Rocket Pharmaceuticals, Inc. (RCKT)
| Market Cap | 423.73M +18.3% |
| Revenue (ttm) | n/a |
| Net Income | -17.25M |
| EPS | -0.15 |
| Shares Out | 109.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,454,755 |
| Open | 3.610 |
| Previous Close | 3.620 |
| Day's Range | 3.530 - 3.990 |
| 52-Week Range | 2.530 - 5.450 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 8.84 (+129.02%) |
| Earnings Date | Aug 10, 2026 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardia... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price target is $8.84, which is an increase of 129.02% from the latest price.
News
Rocket Pharmaceuticals price target lowered to $15 from $16 at Wedbush
Wedbush lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $16 after model adjustments, while keeping an Outperform rating on the shares. The firm says the Q2…
Rocket Pharmaceuticals reports Q2 EPS $1.08, consensus 35c
As of June 30, 2026, Rocket had cash, cash equivalents and investments of $283.7 million. Based on its current operating plan, Rocket expects its cash, cash equivalents and investments as…
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, ...
Rocket Pharmaceuticals Quarterly report: Q2 2026
Rocket Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 10, 2026.
Rocket Pharmaceuticals Earnings release: Q2 2026
Rocket Pharmaceuticals released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Rocket announces safety update from three patients treated with RP-A501
Rocket Pharmaceuticals (RCKT) announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global Phase 2 trial of RP-A501 in Danon dise...
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare an...
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
Rocket Pharmaceuticals (RCKT) announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher, PRV, for gross proceeds of $180M. The Rare Pediatric Disease Priority Review Vouc...
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company has shifted its focus to cardiovascular gene therapies, advancing pivotal trials for Danon and PKP2, and initiating a phase I trial for BAG3. Cash runway extends into Q2 2028, with key regulatory and commercial updates expected this year and next.
Rocket Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a cardiac-focused genetic medicines pipeline, with pivotal trials for Danon and PKP2 and a new phase I for BAG3. Key regulatory and commercial milestones are expected in the second half of the year, supported by a strong cash position and in-house manufacturing.
Rocket Pharmaceuticals price target raised to $10 from $9 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $10 from $9 and keeps a Buy rating on the shares. The firm came away positive…
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Transcript: AGM 2026
The meeting covered board elections, auditor ratification, executive compensation, and a stock option exchange, with all proposals approved and no questions from shareholders. Voting results will be published in a Form 8-K filing.
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
Cash, cash equivalents and investments as of March 31, 2026, were $144.4 million, excluding PRV monetization. “During the first quarter, we continued advancing our cardiovascular gene therapy portfoli...
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Quarterly report: Q1 2026
Rocket Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Rocket Pharmaceuticals Earnings release: Q1 2026
Rocket Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Rocket Pharmaceuticals announces $180M sale of priority review voucher
Rocket Pharmaceuticals (RCKT) announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher, PRV. Rocket has entered into a definitive agreement ...
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Proxy statement: Proxy filing
Rocket Pharmaceuticals filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Rocket Pharmaceuticals Proxy statement: Proxy filing
Rocket Pharmaceuticals filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $9 from $8 and keeps a Buy rating on the shares. Following Kresladi’s approval, the firm…
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
Leerink raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $11 from $9 and keeps a Market Perform rating on the shares after the FDA granted accelerated approval for…
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
LifeSci Capital analyst Patrick Dolezal reiterated an Outperform rating and $9 price target on Rocket Pharmaceuticals (RCKT) after the company announced approval of Kresladi in ultra-rare disease leuk...